We Analyzed the Future Direction of Oramed Pharmaceuticals Inc. (ORMP), Here is What We Found – News Heater
Home  »  Business   »  We Analyzed the Future Direction of Oramed Pharmac...

We Analyzed the Future Direction of Oramed Pharmaceuticals Inc. (ORMP), Here is What We Found

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) went up by 27.90% from its latest closing price compared to the recent 1-year high of $31.54. The company’s stock price has collected 36.62% of gains in the last five trading sessions.

Is It Worth Investing in Oramed Pharmaceuticals Inc. (NASDAQ :ORMP) Right Now?

Plus, the 36-month beta value for ORMP is at 1.99. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Oramed Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $28.00, which is $26.26 above the current price. ORMP currently public float of 36.91M and currently shorts hold a 8.88% ratio of that float. Today, the average trading volume of ORMP was 704.95K shares.

ORMP’s Market Performance

ORMP stocks went up by 36.62% for the week, with a monthly jump of 17.86% and a quarterly performance of -42.02%, while its annual performance rate touched -61.58%. The volatility ratio for the week stands at 12.46% while the volatility levels for the past 30 days are set at 9.22% for Oramed Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 22.68% for ORMP stocks with a simple moving average of -59.12% for the last 200 days.

Analysts’ Opinion of ORMP

Many brokerage firms have already submitted their reports for ORMP stocks, with Cantor Fitzgerald repeating the rating for ORMP by listing it as a “Overweight.” The predicted price for ORMP in the upcoming period, according to Cantor Fitzgerald is $20 based on the research report published on February 18th of the current year 2022.

Canaccord Genuity, on the other hand, stated in their research note that they expect to see ORMP reach a price target of $27. The rating they have provided for ORMP stocks is “Buy” according to the report published on April 20th, 2021.

ORMP Trading at 7.42% from the 50-Day Moving Average

After a stumble in the market that brought ORMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.85% of loss for the given period.

Volatility was left at 9.22%, however, over the last 30 days, the volatility rate increased by 12.46%, as shares surge +24.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.49% lower at present.

During the last 5 trading sessions, ORMP rose by +36.62%, which changed the moving average for the period of 200-days by -71.22% in comparison to the 20-day moving average, which settled at $4.46. In addition, Oramed Pharmaceuticals Inc. saw -62.11% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ORMP starting from RAKIN KEVIN, who sale 10,000 shares at the price of $9.41 back on Mar 21. After this action, RAKIN KEVIN now owns 46,661 shares of Oramed Pharmaceuticals Inc., valued at $94,096 using the latest closing price.

Mayer Arie, the Director of Oramed Pharmaceuticals Inc., sale 3,000 shares at $25.60 during a trade that took place back on Nov 01, which means that Mayer Arie is holding 0 shares at $76,800 based on the most recent closing price.

Stock Fundamentals for ORMP

Current profitability levels for the company are sitting at:

  • -857.68 for the present operating margin

The net margin for Oramed Pharmaceuticals Inc. stands at -822.72. Equity return is now at value -24.00, with -22.30 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 14.27.